Trial
NCT01805791
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hutchison Medipharma Limited
Collaborators
—
Condition
Ulcerative Colitis
Intervention
HMPL-004 1800 mg/day
Why stopped
Interim futility analysis results
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-02